Lv3
220 积分 2025-05-20 加入
Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non–Small Cell Lung Cancer
3天前
已完结
Real-world outcomes of stage III NSCLCs managed by surgery or definitive radiation therapy in the era of immunotherapy
3天前
求助中
Real-world outcomes of stage III NSCLCs managed by surgery or definitive radiation therapy in the era of immunotherapy
2个月前
已关闭
A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer
2个月前
已完结
Tumor immune dynamics and long-term clinical outcome of stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapy
2个月前
已完结
Single-cell and spatial transcriptomic analyses revealing tumor microenvironment remodeling after neoadjuvant chemoimmunotherapy in non-small cell lung cancer
2个月前
已完结
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
2个月前
已完结
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
2个月前
已完结
Single-cell and spatial transcriptomic analyses revealing tumor microenvironment remodeling after neoadjuvant chemoimmunotherapy in non-small cell lung cancer
3个月前
已完结
Neoadjuvant Camrelizumab Plus Platinum-Based Chemotherapy vs Chemotherapy Alone for Chinese Patients With Resectable Stage IIIA or IIIB (T3N2) Non–Small Cell Lung Cancer
4个月前
已完结
皖公网安备34019202002308
